HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions.

Abstract
Women with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and severe ADH are at increased risk of breast cancer, but a systematic quantification of this risk and the efficacy of chemoprevention in the clinical setting is still lacking. The objective of this study is to evaluate a woman's risk of breast cancer based on atypia type and to determine the effect of chemoprevention in decreasing this risk. Review of 76,333 breast pathology reports from three institutions within Partners Healthcare System, Boston, from 1987 to 2010 using natural language processing was carried out. This approach identified 2,938 women diagnosed with atypical breast lesions. The main outcome of this study is breast cancer occurrence. Of the 2,938 patients with atypical breast lesions, 1,658 were documented to have received no chemoprevention, and 184/1,658 (11.1 %) developed breast cancer at a mean follow-up of 68 months. Estimated 10-year cancer risks were 17.3 % with ADH, 20.7 % with ALH, 23.7 % with LCIS, and 26.0 % with severe ADH. In a subset of patients treated from 1999 on (the chemoprevention era), those who received no chemoprevention had an estimated 10-year breast cancer risk of 21.3 %, whereas those treated with chemoprevention had a 10-year risk of 7.5 % (p < 0.001). Chemoprevention use significantly reduced breast cancer risk for all atypia types (p < 0.05). The risk of breast cancer with atypical breast lesions is substantial. Physicians should counsel patients with ADH, ALH, LCIS, and severe ADH about the benefit of chemoprevention in decreasing their breast cancer risk.
AuthorsSuzanne B Coopey, Emanuele Mazzola, Julliette M Buckley, John Sharko, Ahmet K Belli, Elizabeth M H Kim, Fernanda Polubriaginof, Giovanni Parmigiani, Judy E Garber, Barbara L Smith, Michele A Gadd, Michelle C Specht, Anthony J Guidi, Constance A Roche, Kevin S Hughes
JournalBreast cancer research and treatment (Breast Cancer Res Treat) Vol. 136 Issue 3 Pg. 627-33 (Dec 2012) ISSN: 1573-7217 [Electronic] Netherlands
PMID23117858 (Publication Type: Journal Article)
Chemical References
  • Androstadienes
  • Anticarcinogenic Agents
  • Tamoxifen
  • Raloxifene Hydrochloride
  • exemestane
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Androstadienes (therapeutic use)
  • Anticarcinogenic Agents (therapeutic use)
  • Breast Neoplasms (prevention & control)
  • Carcinoma, Ductal, Breast (prevention & control)
  • Carcinoma, Lobular (pathology, prevention & control)
  • Chemoprevention
  • Female
  • Humans
  • Hyperplasia (pathology)
  • Mammary Glands, Human (pathology)
  • Middle Aged
  • Precancerous Conditions (pathology)
  • Raloxifene Hydrochloride (therapeutic use)
  • Tamoxifen (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: